The U.S. Food and Drug Administration approved Farxiga (dapagliflozin) oral tablets to reduce the risk of kidney function decline, kidney failure, cardiovascular death and hospitalization for heart failure in adults with chronic kidney disease who are at risk of disease progression.
- Read more about FDA Approves Treatment for Chronic Kidney Disease
- Log in or register to post comments
source https://www.pharmatutor.org/pharma-news/2021/fda-approves-treatment-for-chronic-kidney-disease
No comments:
Post a Comment